NGM Biopharmaceuticals (NGM) Revenue & Revenue Breakdown
NGM Biopharmaceuticals Revenue Highlights
Latest Revenue (Q)
$165.00K
NGM Biopharmaceuticals Revenue by Period
NGM Biopharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $55.33M | -28.95% |
| 2021-12-31 | $77.88M | -10.86% |
| 2020-12-31 | $87.37M | -15.62% |
| 2019-12-31 | $103.54M | -4.71% |
| 2018-12-31 | $108.67M | 40.87% |
| 2017-12-31 | $77.14M | -9.87% |
| 2016-12-31 | $85.59M | - |
NGM Biopharmaceuticals generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
NGM Biopharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $165.00K | -71.65% |
| 2023-09-30 | $582.00K | -59.10% |
| 2023-06-30 | $1.42M | -36.67% |
| 2023-03-31 | $2.25M | -87.64% |
| 2022-12-31 | $18.18M | 129.82% |
| 2022-09-30 | $7.91M | -4.61% |
| 2022-06-30 | $8.29M | -60.41% |
| 2022-03-31 | $20.95M | -0.05% |
| 2021-12-31 | $20.96M | 12.83% |
| 2021-09-30 | $18.57M | 10.74% |
| 2021-06-30 | $16.77M | -22.26% |
| 2021-03-31 | $21.57M | 9.15% |
| 2020-12-31 | $19.77M | -15.82% |
| 2020-09-30 | $23.48M | 18.87% |
| 2020-06-30 | $19.75M | -18.92% |
| 2020-03-31 | $24.36M | -21.62% |
| 2019-12-31 | $31.08M | 44.12% |
| 2019-09-30 | $21.57M | -14.89% |
| 2019-06-30 | $25.34M | -0.83% |
| 2019-03-31 | $25.55M | -45.77% |
| 2018-12-31 | $47.12M | 126.37% |
| 2018-09-30 | $20.82M | -5.89% |
| 2018-06-30 | $22.12M | 18.83% |
| 2018-03-31 | $18.61M | - |
NGM Biopharmaceuticals generated $165.00K in revenue during Q4 2023, up -71.65% compared to the previous quarter, and up 2.09% compared to the same period a year ago.
NGM Biopharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KZR | Kezar Life Sciences | $7.00M | - |
| GBIO | Generation Bio | $5.90M | $4.06M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| RZLT | Rezolute | - | - |
| CCCC | C4 Therapeutics | - | - |
| NGM | NGM Biopharmaceuticals | - | $165.00K |
| NKTX | Nkarta | - | - |
| NXTC | NextCure | - | - |
| TIL | Instil Bio | - | - |
| ERAS | Erasca | - | - |
| CYT | Cyteir Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| PRLD | Prelude Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
NGM Revenue FAQ
What is NGM Biopharmaceuticals’s yearly revenue?
NGM Biopharmaceuticals's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $55.33M, representing a decrease of -28.95% compared to 2021. NGM's yearly revenue for 2021 was $77.88M, representing a decrease of -10.86% compared to 2020.
What is NGM Biopharmaceuticals’s quarterly revenue?
NGM Biopharmaceuticals's quarterly revenue for Q4 2023 was $165K, a -71.65% decrease from the previous quarter (Q3 2023), and a -99.09% decrease year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $582K, a -59.10% decrease from the previous quarter (Q2 2023), and a -92.64% decrease year-over-year (Q3 2022). NGM's quarterly revenue for Q2 2023 was $1.42M, a -36.67% decrease from the previous quarter (Q1 2023), and a -82.84% decrease year-over-year (Q2 2022).
What is NGM Biopharmaceuticals’s revenue growth rate?
NGM Biopharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.